drughunter.com
12 minute read
Oct. 11, 2024

Key Clinical Compound Updates from September 2024

Loading...

twitterlinkedinemail

Other articles you may be interested in

Molecules on the Move: April '23

This article compiles 20+ recent small molecules of general interest in the news in April 2023, with structures where they are available. Capacity Bio’s MAS Receptor Agonists with $35M Raised for FIH Clinical Trials MAS modulator from WO2022165189 example 107 New start-up Capacity Bio backed by RA Capital, Insight Partners, and Remiges [...]

May 2024 Molecule Roundup

To select May’s Molecules of the Month, our team evaluated hundreds of molecules from thousands of papers, press releases, conference presentations, and other materials. Check out our curated roundup of more than 60 additional molecules below that caught our interest from May, including highlights of some of our favorites, and perspectives on why these are molecules to watch.

August 2024 Molecule Roundup | >70 Molecules to Know

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

June 2024 News Roundup: FDA Approvals, Major Deals, Obesity Research Advances, and More

In June, we saw several FDA approvals for treatments targeting primary biliary cholangitis and COPD. The industry witnessed multibillion- and multimillion-dollar deals across various therapeutic areas. Advances were made in obesity therapeutics, with novel targets and clinical readouts for GLP-1 agonists and NLRP3 inhibitors. Alkermes and Takeda reported results for OX2R agonists in narcolepsy, while an antimalarial drug showed promise in PCOS. Despite these advancements, there were clinical trial failures for key molecules. Here's a recap of the most notable news highlights from June 2024!

Key Clinical Compound Updates from August 2024

Here’s a rundown of August’s key clinical developments, including FDA approvals, potential upcoming approvals, notable trial readouts, new NDA submissions, and pipeline realignments.